Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

BioStock: Medivir continues to accelerate development with fostrox

Medivir’s recently published Annual Report for 2023 focuses primarily on the drug candidate fostrox. Clinical data shows improved efficacy in patients with advanced primary liver cancer when the drug is combined with Lenvima. The company continues to accelerate clinical development with the aim of establishing fostrox as the first approved treatment for second-line liver cancer. BioStock reached out to the company’s CEO Jens Lindberg for a comment on the past year, and to learn of his expectations for the rest of 2024.Read the full interview with Jens Lindberg at biostock.se: https://www.

Invitation to Fabege’s presentation of the interim report Jan-Mar

On Thursday 25 April 2024 at 07:00 (CET), Fabege’s interim report Jan-Mar 2024 will be published. Investors, analysts, journalists, and other stakeholders are invited to participate in an audiocast and teleconference at 10:30 (CET) the same day.Stefan Dahlbo, President and CEO, and Åsa Bergström, Vice President and CFO, will be presenting Fabege’s Year-end report 2023. The presentation will be held in English and will conclude with a Q&A session. A presentation in Swedish will also be held on the same day at 09:00 (CET). Join the audiocast via the following web link:https://

Artificial Solutions signs agreement with MedHelp Care for AI-Based voice chatbot

Artificial Solutions (www.teneo.ai) begins collaboration with MedHelp Care, which offers one of Sweden's most used health platforms for employers. The company's roughly 500 customers with approximately 200,000 employees, will also have the opportunity for AI-based absence reporting via telephone through a voice chatbot from the AI platform Teneo. With more than 20 years of experience in healthcare advice, MedHelp Care handles several hundred thousand healthcare calls each year.Artificial Solutions will integrate Teneo's voice chatbot into MedHelp Care's telephone service. This will reduce

Arctic Bioscience – Notice of Annual General Meeting on 26 April 2024

Arctic Bioscience AS’ Annual General Meeting will be held Friday 26 April 2024 at 11:00 (CET), as a digital meeting.Shareholders are encouraged to cast their votes in advance of the General Meeting or grant the Chair of the Board a proxy, with or without voting instructions. Deadline for registration of attendance, advance votes, proxy or instructions is 24 April 2024 at 16:00 (CET). For attendance to the live event, please follow the instruction in the notice. For further information, see the attached Notice of the Annual General Meeting, which can also be accessed from the company’s

New 2024 Report Unveils Shifts in Expense Management Across Europe

A recently released report, “State of Expense Management 2024”, sheds light on the evolving practices in expense management. It emphasises the critical shift towards digital solutions and the broadening of expense management responsibilities across organisations in six European countries.Findity is a leading provider of expense management solutions in Europe and can see firsthand how expense management is evolving at rapid speed through its extensive partner network. More and more organisations begin to see the time savings and efficiency that a digital solution brings. "The way

Förvaltaren and Zengun sign construction contract for Kvarnstugan block

The public housing property company Fastighets AB Förvaltaren has signed a construction contract with Zengun for the next phase of the production of the Kvarnstugan block in Sundbyberg. The project encompasses 113 rental apartments, a café, restaurant and cultural facilities. The order volume amounts to approximately MSEK 400. [A building with many windows Description automatically generated] Vision picture: Belatchew Arkitekter Centrally located by Ursvik torgThe Kvarnstugan block will have a central location by the square forming Ursvik torg in Sundbyberg’s new western Ursvik

Transaction in Own Shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION 11 April 2024 REDDE NORTHGATE PLC (“Redde Northgate” or the “Group” or the “Company”)   Transaction in Own Shares   Redde Northgate plc (LSE:REDD) announces that on 11 April 2024 it purchased the following number of its own shares to be held in treasury:   Class of shares :  Ordinary shares of 50p (“shares”)Number of

Granf of Performance Shares

Oslo, 12 April 2024: Reference is made to the implementation of BlueNord ASA’s ("BlueNord" or the "Company") Long-Term Incentive Scheme (“LTI”) as announced on 19 September 2022. Under the LTI programme an additional 90,234 BlueNord shares have been granted of which the BlueNord executive team has been allocated the following: · Euan Shirlaw: granted a maximum of 13,187 shares, with total allocation of performance shares of maximum 47,319 shares under the LTI. In addition, Shirlaw has the right to receive 60,014 retention shares and he owns 3997 ordinary shares. · Marianne Eide:

Tokmanni Group’s Report by the Board of Directors and Financial Statements, Corporate Governance Statement and Remuneration Report for 2023 published

Tokmanni Group Corporation        Stock exchange release        12 April 2024 at 10:30 amTokmanni Group Corporation’s Report by the Board of Directors and Financial Statements 2023 have been published today. The Report by the Board of Directors includes the statement of non-financial information. The Financial Statements are also published in Finnish in accordance with the European Single Electronic Format (ESEF) reporting requirements. The format is Extensible Hypertext Markup Language (XHTML). In line with the ESEF requirements, the primary financial statements have been labelled with

Publishing of Qt Group’s Interim statement on April 25, 2024

Qt Group Plc will publish its Interim statement for January 1 – March 31, 2024, on Thursday, April 25, 2024, approximately at 1:00 pm EEST. The report will be available after publishing at www.qt.io/investors .  News conference  Qt Group will organize a news conference on April 25, 2024, at 3:30 – 4:30 pm EEST in Helsinki, Finland, and as a live webcast at www.qt.io/investors . CEO Juha Varelius and CFO Jouni Lintunen will be presenting the results. An on-demand recording will be available later on the same

Recruitment milestone reached in Diamyd® Phase 3 trial

Diamyd Medical’s precision medicine Phase 3 trial for Type 1 Diabetes, DIAGNODE-3, has enrolled 100 patients. To date, no serious adverse events have been reported, and no patients have discontinued the trial.“This is an important milestone in our Phase 3 trial and the notable zero dropout rate confirms our insights from previous trials regarding the safety and convinience of the treatment,” says Ulf Hannelius, President & CEO of Diamyd Medical. “We are deeply grateful to our participants for their continued commitment to the trial and to the dedicated staff at our participating clinics for

Correction to previous annoucement No 043: WindowMaster narrows the 2024 guidance in the high end of the previous announced range:

Company announcement - No. 044-2024 - Insider InformationVedbaek,12 April 2024Record high order intake for Q1 2024 · Order intake reached a record high level end of Q1 amounted to DKK 74m for Q1 2024 and DKK 268m 12-month-running (2023: DKK 60m for Q1 and DKK 244m 12-month-running). This represents a growth of 24% for the quarter and 10% 12-month-running. The strong growth is coming from all our main markets (except Nordic) and is seen as being able to deliver on the strategy “Accelerate-Core” as it is mainly the project business driving the growth. We also see some improvements from

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 85 – 12 APRIL 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 30/24 and 31/24.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Communications & Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

BioStock: CLS makes progress in prostate cancer in Europe and the US

Clinical Laserthermia Systems has treated its first prostate cancer patients in Italy and secured additional orders and agreements in the US. In addition, the company has presented initial clinical data from the study at Radboud University Medical Center in the Netherlands.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/cls-makes-progress-in-prostate-cancer-in-europe-and-the-us/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Invitation to presentation of Betsson AB’s results for the first quarter of 2024

On Friday, 26 April 2024 at 07:30 CEST, Betsson will publish its interim report for the first quarter of 2024. At 9:00 CEST on the same day, Betsson invites analysts, investors, and media to participate in the presentation of the results.The results will be presented by CEO Pontus Lindwall and CFO Martin Öhman. The presentation will be held in English, followed by a Q&A session. Participants are welcome to join via webcast or phone. Link with information on how to participate in the webcast and telephone conference: https://financialhearings.com/event/49076   For further

Invitation to Saab’s Q1 2024 interim report presentation

Saab’s CEO and President Micael Johansson and CFO and deputy CEO Christian Luiga will present Saab’s interim report for January-March 2024.Date: Friday 26 April at 10:00 a.m. (CET).  The report is published at 07.30 a.m. (CET) the same day at www.saab.com. You are welcome to watch the live webcast or dial in to the conference call. It is possible to submit questions over the conference call and from the webcast page. Live webcast: www.saab.com/investors/webcast/q1-2024  Registration for conference call: www.saab.com/investors/conference-call-Q1 The interim report,

BioStock: Respiratorius’ US patent application reopens

After the initial rejection of Respiratorius’ patent application, the US Patent and Trademark Office’s Patent Trial and Appeal Board has now sided with the company. The decision means a reopening of the application regarding the oral formulation of VAL001. BioStock has contacted CEO Johan Drott to gain a better understanding of what this implies for the project.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/respiratorius-us-patent-application-reopens/ This is a press release from BioStock - Connecting Innovation & Capital. https:/

Odfjell introduces an innovative transition finance framework

Odfjell has passed another significant milestone on its transition journey with the introduction of a ‘Transition Finance Framework’. The initiative is a first in the Nordic region and solidifies the shipping company’s position at the forefront of sustainable finance practices.Odfjell has worked actively to reduce emissions for more than a decade. This work has led to documented results, positioning the chemical tanker operator as a sustainability leader in the international shipping industry. The company is now taking another proactive step toward reaching its ambitious climate targets by

BoMill Q1 Report January – March 2024

BoMill AB (”BoMill” or the “Company”) hereby publishes the Interim Report for the period January 1 – March 31, 2024. The Report is available as an attached file to this release and on BoMill’s website. Below is a summary of the report.POSITIVE START OF 2024 WITH NEW ORDERS CEO Andreas Jeppsson comments: “2024 has started very well for BoMill InSight™ with our agreement with Lantmännen and the repeat order from Baltijos Javai to increase capacity. I’m confident we are on the right track for success.” Net sales and income for the first quarter (January – March 2024)        · Net

Dicot in preparation for clinical phase 2a trial

Press release: Uppsala, Sweden, April 12, 2024. The pharmaceutical company Dicot, which recently announced that a reporting from the last part of the phase 1 study will be published at the end of April, is in parallel preparing for a clinical phase 2a trial with its potency drug candidate. Today, the company can announce that a partner has been contracted to conduct the trial and that the study drug has been produced by Thermo Fisher Scientific, the contracted manufacturer.Dicot will soon report the results from the last part in the clinical phase 1 study. In parallel, preparatory

There are no items matching the current filter
There are no more items matching the current filter
Back to top